CD274 and neoplasm: This enhanced efficacy is likely attributed to the delivery of IL-2v through the anti-PD-L1 moiety, as evidenced by increased tumor cell killing when IL-2v is combined with anti-PD-L1 (Supplementary Fig. 3).